Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Outperform Rating at Leerink Partnrs

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Partnrs in a report issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 […]

Related Keywords

Switzerland ,Swiss ,Leerink Partnrs ,Needham Company ,Commonwealth Equity Services ,Nasdaq ,Lexicon Pharmaceuticals Trading ,Lexicon Pharmaceuticals ,Lexicon Pharmaceuticals Inc ,News Ratings For Lexicon Pharmaceuticals Daily ,Sg Americas Securities ,Swiss National Bank ,National Association ,Get Free Report ,Equity Services ,National Bank ,Lexicon Pharmaceuticals Daily ,Nasdaq Lxrx ,Lxrx ,Medical ,52887210 ,Reiterated Rating ,